Calcitriol - Berg Pharma

Drug Profile

Calcitriol - Berg Pharma

Alternative Names: 31543; API-31543; BPM-31543

Latest Information Update: 06 Apr 2016

Price : $50

At a glance

  • Originator Berg Pharma
  • Developer Cure Pharmaceutical
  • Class Antipsoriatics; Chemoprotectants; Dihydroxycholecalciferols; Osteoporosis therapies; Small molecules; Vitamin D analogues
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alopecia
  • Preclinical Myelosuppression

Most Recent Events

  • 06 Apr 2016 Phase-I development is ongoing for Alopecia in USA
  • 15 Mar 2016 Biomarkers information updated
  • 25 Jul 2012 Chemical structure added (USAN); str saved as MOL and PNG files
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top